Abi Manesh
@abimaneshID
Followers
73
Following
96
Media
0
Statuses
76
ID physician, CMC Vellore, India
Tamil Nadu
Joined February 2022
We’re delighted to share highlights from our recent workshop “Framing JUST solutions for ACCESS to treatment against AMR”! Fantastic participants, candid challenge-sharing, and lively, solutions-focused discussions throughout the day. Read more: https://t.co/WhhFKEI7E2
0
3
2
Big thanks to a great group of co-authors - Current and future options for the treatment of serious infections due to carbapenem-resistant Pseudomonas aeruginosa | Clinical Microbiology Reviews
journals.asm.org
SUMMARYPseudomonas aeruginosa is a frequent cause of hospital-acquired infections and is notable both for its virulence and its resistance to multiple antibiotics. In the absence of head-to-head...
1
7
34
New RCT from @UQMedicine Cefiderocol versus standard therapy for healthcare-associated Gram-negative BSI @UQ_GAMECHANGER @UQ_News >500 patients in 6 countries with high rates of MDR; 25% carb-R; Non-inferior but not superior for 14d mortality @TheLancetInfDis @davidantibiotic
4
13
32
✨ We’re excited to have Dr Nguyen Thi Kim Anh join the ADVANCE-ID team! Get to know her in this short introduction. #WelcomeOnboard #ADVANCE_ID #AMR #ClinicalTrials #Research #Singapore
0
2
4
Congratulations @OffCMCVellore on retaining #NIRF ranking as 3rd best Medical College in India. @dpradhanbjp Benchmarks help but staying true to the call to "Not to be ministered unto, but to minister" will define who we really are meant to be. Three cheers to the Silver & Blue
0
11
36
📅 Save the Date: ACC2026 The Antimicrobial Chemotherapy Conference (ACC2026) is coming your way in February 2026! This year, GARDP and @BSACandJAC are teaming up with @ADVANCE__ID and @MahidolU to develop this one-of-a-kind online conference. 🗓️ Programme details and
0
8
20
🚀 Join us in welcoming Dr Iris Chang to the ADVANCE-ID team! Here’s a brief introduction to get to know her better! #WelcomeOnboard #ADVANCE_ID #AMR #ClinicalTrials #Research #Singapore
0
1
8
Welcome Iris! So great to have you sharing your extensive experience with resistant GNBs with us!
🚀 Join us in welcoming Dr Iris Chang to the ADVANCE-ID team! Here’s a brief introduction to get to know her better! #WelcomeOnboard #ADVANCE_ID #AMR #ClinicalTrials #Research #Singapore
0
4
13
A new @guardian article highlights the alarming economic impact of AMR if we continue business as usual. The report findings are — 💸 $2 trillion in global economic losses annually by 2050 📷 Millions of lives at risk from drug-resistant infections Cuts to AMR programmes,
theguardian.com
Exclusive: Research on burden of antibiotic resistance for 122 countries predicts dire economic and health outcomes
0
4
4
@DBTIndia @wellcometrust @rajesh_gokhale @jarottingen @SunilLaxman @TPucadyil @Ludwig_Cancer @UCSanDiego @IGIBSocial @IISERPune @DBT_inStem Next in the conclave, we held a poster session where our fellows and grantees presented their work, creating a forum for discussion, exchanging diverse ideas, and sharing new findings.
0
1
1
Proper contingent at the 13th Conclave @India_Alliance 2025. Fellows: @abimaneshID, @rohan_mic, @MahasampathG, Poonguzhali B; Team Science: Arul P Lionel, @SaravanabhavanT, Mohan Kumar Murugesan @CSCR_CMC_inStem; CRC&CRTP: Respind-Net @mahesh_moorthy -among others @OffCMCVellore
0
2
4
🚀 Join us in welcoming Dr Abi Manesh to the ADVANCE-ID team! Here’s a brief introduction to get to know him better! #WelcomeOnboard #ADVANCE_ID #AMR #ClinicalTrials #Research #Singapore @abi_manesh
0
3
12
We commence Day 1 of our 13th Annual Conclave 2025 today, a three-day event happening from 16–18 July. The day opened with Lightning Talks, where our Fellows gave a rapid overview of their research. Follow this thread for more updates and highlights from Day 1 of the Conclave.
2
6
18
🚩 A milestone in the fight against #AMR Congratulations to @Roche on advancing zosurabalpin into Phase 3 trials—a potential first-in-class antibiotic against Carbapenem-resistant Acinetobacter baumannii and other Gram-negative bacteria in over 50 years. This kind of bold
ft.com
If successful, it would be the first new class of drug against certain bacteria strains for more than 50 years
0
9
12
https://t.co/fLS1r7RVrA Landmark study with international collaboration & CMC partnership conducted across diverse range of hospitals in countries in 3 continents - #India, #Brazil & #Malawi - showed improvement in diagnosis and management for #patients with acute brain
thelancet.com
Diagnosis and management of patients with suspected acute brain infections improved following introduction of a simple intervention package across a diverse range of hospitals on three continents....
0
6
33
This insightful study highlights the alarming burden of scrub typhus in India. Great work; Congratulations to @Carol Devamani @Wolf-Peter Schmidt! @MOHFW_INDIA @ICMRDELHI @NCDC_GoI @WHOIndia @WHOSEARO @WHO @CIDS_INDIA @RSTMH @CMC_Vellore @MORUBKK @npjday
https://t.co/7HAiHKQwie
2
18
67
ICMR AMR team will be sharing Indian experiences from Antimicrobial resistance surveillance network at IVI AMR TRAINING @IVIHeadquarters @seoul @ICMRDELHI
0
10
42
One of life’s greatest joys is to spread the gospel of the superiority of ORAL antibiotics All are welcome in our church! At our next ceremony we will be burning PICC lines and reciting the liturgy of oral bioavailability
7
12
80
#UQ researchers collaborated with 5 leading hospitals in Australia to investigate gram negative bloodstream infections in children. The results will help prioritise future antimicrobial clinical trials. https://t.co/XoR1fAsjXQ
@padstamundo @davidantibiotic
academic.oup.com
A total of 931 gram-negative bloodstream infection episodes involving 818 children were studied. The children were typically young and medically complex. E
0
4
8
Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial https://t.co/y43lAVd6gy
academic.oup.com
The win ratio is a method for assessing trial outcome using a hierarchical composite endpoint. Using its application post hoc to the MERINO trial provided
0
25
52